Related Experiment Videos
Active-specific immunization against melanoma: is the problem at the receiving end?
Vladia Monsurrò1, Ena Wang, Monica C Panelli
1Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bldg. 10, R-1C711 National Institutes of Health, Bethesda, MD, USA.
Seminars in Cancer Biology
|March 6, 2004
Summary
Modern biotechnology advances tumor immunology, identifying tumor antigens to create T cells. However, these T cells struggle to eliminate tumors, highlighting the need to understand T cell function within the tumor microenvironment.
Area of Science:
- Tumor immunology and cancer research
- Immunotherapy and biotechnology applications
Background:
- Significant progress in tumor immunology has been achieved through modern biotechnology.
- Identification of tumor antigens has enabled active immunization to induce tumor antigen-specific T cells.
Purpose of the Study:
- To address the paradox of T cells recognizing tumor cells but failing to induce tumor regression.
- To explore the limitations of T cell effector function within the tumor microenvironment.
Main Methods:
- Review of T cell physiology and tumor biology.
- Analysis of active immunization trial outcomes.
- Conceptual framework for understanding T cell-mediated tumor rejection.
Main Results:
- Immunization-induced T cells can recognize tumor cells in vitro.
- Despite recognition, these T cells often fail to cause tumor regression in vivo.
- Successful tumor clearance requires more than just antigen-specific T cell induction.
Conclusions:
- The inability of T cells to induce tumor regression is linked to factors beyond antigen recognition.
- Further research is needed to understand T cell localization and function within the tumor microenvironment.
- Overcoming the tumor microenvironment's resistance is crucial for effective cancer immunotherapy.